share_log

Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023

Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023

葉科學出席亮相大麻 & 迷幻學會議四月 5, 2023
newsfile ·  2023/04/04 20:01

Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that Philip Young, CEO and Executive Chairman, will present at the SEQUIRE CANNABIS & PSYCHEDELICS CONFERENCE, April 5th at 10:00AM EDT.

溫哥華,不列顛哥倫比亞省-(Newsfile Corp.-2023年4月4日)-Llobe Sciences Ltd.(CSE:LOPE)(場外交易市場:LOBEF)(“波瓣“或”公司)一家致力於發現和開發治療孤兒和罕見疾病的以患者為中心的藥物的北美生物製藥公司今天宣佈,首席執行官兼執行主席菲利普·楊將出席4月5日舉行的SEQUIRE大麻和迷幻藥物會議這是美國東部時間上午10:00。

Registration for the event is accessible via the following link Sign up free.

可通過以下鏈接訪問活動的註冊免費註冊

About Lobe Sciences Ltd.

關於波爾科學有限公司

Lobe Sciences is a biopharmaceutical company focused on developing patient-friendly, easily administered medicines for orphan and rare diseases. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using sub-hallucinatory doses of our proprietary compounds targeting and treating orphan and rare diseases. Each of our New Chemical Entities, L-130 and L-131, are being developed to address unmet medical needs in patient populations where there are few, if any therapeutic options.

Lobe Sciences是一家生物製藥公司,專注於開發對患者友好、易於管理的治療孤兒和罕見疾病的藥物。該公司通過與業界領先的合作夥伴合作,利用我們針對和治療孤兒和罕見疾病的專有化合物的亞幻覺劑量,從事藥物研究和開發。我們正在開發每一種新的化學實體,L-130和L-131,以滿足患者群體中未得到滿足的醫療需求,這些患者幾乎沒有治療選擇。

For further information please contact:

欲瞭解更多資訊,請聯繫:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

洛普科學有限公司。
首席執行官菲利普·J·楊
郵箱:Info@lobesciences.com
電話:(949)505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

CSE及其監管服務提供商均未對本新聞稿的準確性或充分性進行審查或承擔責任。

This does not constitute an offer to sell or a solicitation of offers to buy any securities.

這不構成出售要約或邀請買入任何證券的要約。

Forward Looking Statements

前瞻性陳述

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this news release (including, without limitation, statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness) are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company's drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company's corporate goals and objectives; and other risk factors detailed in the Company's continuous disclosure filings from time to time, as available under the Company's profile at . As a result, the Company cannot guarantee that any forward-looking statement will materialize, and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

本新聞稿包含與公司未來業務有關的前瞻性陳述,以及其他非歷史事實的陳述。前瞻性陳述通常用“將”、“可能”、“應該”、“預期”、“預期”和類似的表達方式來識別。除歷史事實陳述外,本新聞稿中包含的所有陳述(包括但不限於有關公司未來計劃和目標、使用迷幻化合物的研究和開發,以及改善精神健康和健康的創新設備和交付機制的開發)均為前瞻性陳述,涉及風險和不確定性。不能保證這樣的陳述將被證明是準確的,實際結果和未來事件可能與此類陳述中預期的大不相同。請讀者注意,在編制前瞻性陳述時使用的假設可能被證明是不正確的。事件或情況可能會導致實際結果與預期大不相同,原因是許多已知和未知的風險、不確定性和其他因素,其中許多是公司無法控制的,包括監管環境的變化;公司的藥物研發活動可能不成功;公司生產的或代表公司生產的藥品和醫療器械可能不以預期的方式或根本不起作用,並可能使公司承擔產品責任或其他責任索賠;公司可能無法實現公司的公司目標和目的;以及在公司不時提交的持續披露檔案中詳細說明的其他風險因素,可在公司簡介中查閱,網址為。因此,公司不能保證任何前瞻性陳述都會成為現實,並告誡讀者不要過度依賴任何前瞻性資訊。本新聞稿中包含的前瞻性陳述明確地受到本警示性聲明的限制。本新聞稿中包含的前瞻性陳述僅在本新聞稿發佈之日作出,公司不打算更新任何包含的前瞻性陳述,除非適用的加拿大證券法明確要求。

Drug development involves long lead times, is very expensive and involves many variables of uncertainty. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. Every patient treated on future studies can change those assumptions either positively (to indicate a faster timeline to new drug applications and other approvals) or negatively (to indicate a slower timeline to new drug applications and other approvals). This news release may contain certain forward-looking statements regarding anticipated or possible drug development timelines. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company's development efforts to date. In addition to the risk factors set out above and those detailed in the Company's continuous disclosure filings from time to time, as available under the Company's profile at , other factors not currently viewed as material could cause actual results to differ materially from those described in the forward-looking statements. Although Lobe has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be anticipated, estimated or intended. Accordingly, readers should not place any undue reliance on forward-looking statements.

藥物開發需要很長的準備時間,非常昂貴,並且涉及許多不確定的變量。有關藥物開發的預期時間表是根據公司現有的知識和資訊做出的合理假設。在未來的研究中接受治療的每個患者都可以改變這些假設,要麼是積極的(表明新藥申請和其他批准的時間表更快),要麼是負面的(表明新藥申請和其他批准的時間表更慢)。本新聞稿可能包含有關預期或可能的藥物開發時間表的某些前瞻性陳述。此類陳述的依據包括開發藥物的監管指南、安全性研究、概念驗證研究以及新藥申請提交和批准的關鍵研究,並假定此類指南、其他行業實例以及該公司迄今的開發努力所表明的時間表上此類研究的成功實施和結果。除上述風險因素及本公司不時提交的持續披露檔案中所詳述的風險因素外,此外,目前未被視為實質性因素的其他因素可能導致實際結果與前瞻性陳述中描述的結果大相徑庭。儘管LOB試圖確定可能導致實際行動、事件或結果與前瞻性陳述中描述的大不相同的重要風險和因素,但可能存在其他因素和風險,導致行動、事件或結果不可預期、估計或預期。因此,讀者不應過分依賴前瞻性陳述。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論